A prospective Canadian cohort study suggested that serious underlying arrhythmia was often identified within the first 2-hours of emergency department (ED) arrival for low-risk patients, and within 6-hours for medium- and high-risk patients. Outpatient cardiac rhythm monitoring for 15-days for selected medium-risk patients and all high-risk patients discharged from the hospital should also be considered. There were 5,581 patients (mean age 53.4 years, 54.5% females, 11.6% hospitalized) available for analysis, including 346 (6.2%) censored due to incomplete 30-day follow-up. 417 (7.5%) patients suffered serious outcomes of which 207 (3.7%) were arrhythmic (161 arrhythmias, 30 cardiac device implantations, 16 unexplained death). Overall, 4123 (73.9%) were classified as Canadian Syncope Risk Score low-risk, 1062 (19.0%) medium and 396 (7.1%) high-risk. The score accurately stratified subjects as low (0.4% risk for 30-day arrhythmic outcome), medium (8.7% risk) and high-risk (25.3% risk). One-half of arrhythmic outcomes were identified within 2-hours of ED arrival in low-risk and within 6-hours in medium and high-risk patients and the residual risk after these cut-points were 0.2% for low-risk, 5.0% medium and 18.1% high-risk patients. Overall, 91.7% of arrhythmic outcomes among medium and high-risk patients including all ventricular arrhythmias were identified within 15-days. None of the low-risk patients suffered ventricular arrhythmia or unexplained death while 0.9% medium-risk and 6.3% of high-risk patients suffered them. Source: https://www.ahajournals.org/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.